Kiniksa Pharmaceuticals International, plc
KNSA
$19.31
$0.663.54%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 56.60% | 54.41% | 20.69% | 27.69% | 22.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 56.60% | 54.41% | 20.69% | 27.69% | 22.74% |
| Cost of Revenue | 110.41% | 92.76% | 101.66% | 112.76% | 91.48% |
| Gross Profit | 29.77% | 37.01% | -2.64% | 4.97% | 4.11% |
| SG&A Expenses | 29.81% | 36.96% | 38.30% | 32.72% | 32.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.69% | 53.12% | 50.97% | 54.97% | 40.42% |
| Operating Income | -81.04% | -36.43% | -172.17% | -239.49% | -357.81% |
| Income Before Tax | -117.10% | -36.39% | -141.94% | -186.44% | -251.02% |
| Income Tax Expenses | 122.91% | -37.46% | 95.86% | 82.37% | 82.17% |
| Earnings from Continuing Operations | -406.68% | -35.51% | -104.42% | -95.59% | -92.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -406.68% | -35.51% | -104.42% | -95.59% | -92.32% |
| EBIT | -81.04% | -36.43% | -172.17% | -239.49% | -357.81% |
| EBITDA | -92.17% | -45.01% | -163.03% | -216.89% | -287.72% |
| EPS Basic | -403.66% | -30.39% | -104.34% | -95.59% | -92.44% |
| Normalized Basic EPS | -111.82% | -34.40% | -141.32% | -185.29% | -252.41% |
| EPS Diluted | -424.39% | -24.75% | -104.79% | -95.90% | -92.70% |
| Normalized Diluted EPS | -111.25% | -33.57% | -142.35% | -188.67% | -266.63% |
| Average Basic Shares Outstanding | 1.95% | 1.53% | 1.25% | 1.08% | 0.99% |
| Average Diluted Shares Outstanding | 0.51% | 1.09% | 0.42% | 1.48% | 1.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
